A central insight emerging from the GLP-1 experience is that biological pleiotropy does not preclude therapeutic utility
The biology is plausible (gut mucosal protection) but theres no trial data supporting this claim
However, real-world patient data shows meaningful individual variation
Published literature varies widely on dosage regimens, with an emphasis on the importance of gradual dose selection under the direct support and monitoring of a medical doctor to assess clinical tolerance and individual response assessment
4 min read If youve recently scrolled through any wellness or weight loss forums, youve likely seen talk about microdosing GLP-1 medications
It increases the risk of: Type 2 diabetes Non-alcoholic fatty liver disease (NAFLD) Cardiovascular disease Simultaneously, the loss of estrogen accelerates sarcopenia , the loss of lean muscle mass, which further slows metabolism and reduces energy expenditure